Syndivia Raises €1M Investment to Advance Its Tumour Microenvironment Drug Delivery Platform

On December 10, 2019 Syndivia, a biotechnology company focused on the development of new therapeutic modalities for solid cancers based on specific targeting of the tumour microenvironment and anatomical hallmarks, reported a €1 million investment from Cap Innov’Est, an inter-regionally based seed fund (Press release, Syndivia, DEC 10, 2019, View Source [SID1234552214]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This funding will enable Syndivia to advance its pipeline of proprietary anticancer therapies, including its lead drug candidate (SDV1001), thus completing the preclinical "proof of concept" study of the targeting of the microenvironment of solid tumours.

Sasha Koniev, Syndivia’s CEO, said, "We are very pleased to see Cap Innov’Est joining the company’s founders. This funding will allow us to advance our drug platform for both small-molecule and biologics, which have the unique potential to address a wide range of solid cancer indications by harnessing the specific properties of the tumor microenvironment."

Jean-François Rax, Investment Director at Cap Innov’Est said, "We are truly enthusiastic to be investing in such a promising company. We are convinced that Syndivia’s breakthrough approach in the hands of its experienced management team will be successful in delivering innovative and efficient treatments for cancer patients."

Select Medical Corporation Closes Private Placement of $675 Million of 6.250% Senior Notes due 2026

On December 10, 2019 Select Medical Holdings Corporation ("Holdings") (NYSE: SEM), reported that Select Medical Corporation ("Select") has completed its private placement of $675 million aggregate principal amount of its 6.250% Senior Notes due 2026 as additional notes (the "Additional Notes") under same indenture as Select’s existing $550 million aggregate principal amount of 6.250% senior notes due 2026 that were originally issued on August 1, 2019 and, as such, will form a single series and trade interchangeably with such previously issued notes (Press release, Select Medical, DEC 10, 2019, View Source;300972584.html [SID1234552213]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Selects intends to use a portion of the net proceeds of this offering, together with a portion of the net proceeds from a $615 million incremental term loan and, if required, available cash, to loan to its joint venture subsidiary, Concentra, Inc. ("Concentra"), pursuant to the terms of an intercompany loan agreement, an amount which will be used by Concentra to repay in full all currently outstanding term loan indebtedness under Concentra’s first lien credit agreement. Any remaining net proceeds from the offering will be used by Select for general corporate purposes.

The notes and related guarantees were sold in a private placement, solely to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), or outside the United States to persons other than "U.S. persons" in compliance with Regulation S under the Securities Act. The notes and related guarantees have not been registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

This notice does not constitute an offer to sell the notes, nor a solicitation for an offer to purchase the notes, in any jurisdiction in which such offer or solicitation would be unlawful. Any offer of the notes will be made only by means of a private offering memorandum. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

Ascentage Pharma Releases Updated Data of its Novel BCR-ABL Inhibitor, HQP1351, in an Oral Presentation Nominated for "Best of ASH"

On December 10, 2019 Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, reported that the updated results from the Phase I study of the company’s novel investigational drug HQP1351 were reported in an oral presentation at the 61st American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition (Press release, Ascentage Pharma, DEC 10, 2019, View Source [SID1234552212]). The presentation titled "Updated Safety and Efficacy Results of Phase I Study of HQP1351, a Novel 3rd Generation BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia" was delivered by the principal investigator of the study, Qian Jiang, M.D., from Peking University People’s Hospital. In addition, the presentation data was nominated for the "Best of ASH (Free ASH Whitepaper)", a recognition that only a handful of innovative clinical programs from China have achieved.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HQP1351 is a novel, orally active potent 3rd generation BCR-ABL Tyrosine Kinase Inhibitor (TKI) under development for the treatment of patients with chronic myeloid leukemia (CML) resistant to current TKI-therapies including those with T315I mutation.

Key results from the trial:

The study is a Phase 1 trial of HQP1351 in Chinese patients with TKI-resistant CML in the chronic phase (CP) or accelerated phase (AP). Patients received treatment in one of the eleven dose cohorts ranging from 1mg to 60mg. 60mg QOD was identified as the dose-limiting toxicity (DLT) dose, 50mg QOD was considered as the maximum-tolerated dose (MTD), and 40mg was identified as RP2D;
As of May 27, 2019, 101 CML patients including 87 CP patients and 14 AP patients were enrolled in the study. The median duration of follow-up was 12.8 months (range, 1.2-31.5). The 18-month progression free survival (PFS) rate was 94% in CP and 61% in AP;
HQP1351 was well-tolerated in all dose cohorts with the exception of the 60mg cohort. Of all the treatment-related adverse events (TRAEs), most of the non-hematologic TRAEs were reported as Grade 1 or Grade 2; the most common hematologic TRAE of Grade 3/4 was thrombocytopenia (50%). The incidence of TRAEs declined with longer duration of treatment. No treatment-related deaths or Grade 5 AEs occurred;
HQP1351 showed potent anti-leukemic activities and a high response rate in TKI-resistant CML patients. The response rate and the depth of responses were further improved with longer duration of treatment. In the evaluable patients, the complete hematologic response (CHR) rate was 95% in CP and 85% in AP;
In the 95 evaluable patients with non-complete cytogenetic response (non-CCyR) at baseline, 69% of the CP patients achieved a major cytogenetic response (MCyR), of which 61% achieved a complete cytogenetic response (CCyR); 43% of the AP patients achieved MCyR, of which 36% achieved CCyR;
In the evaluable patients, the major molecular response (MMR) rate was 37% in CP and 36% in AP;
HQP1351 showed strong response in TKI-resistant CML patients with the T315I mutation. Among the T315I-mutant CP patients, the MCyR rate was 82%, and the CCyR rate was 78%.
"Drug-resistance to TKIs is an urgent unmet need and a major challenge in the treatment of CML. No third-generation TKI is currently approved in China, and no imported third-generation TKIs are expected to enter China in the foreseeable future," said presenting author Dr. Qian Jiang. "The updated results from this Phase I trial of HQP1351 have further validated its tolerability and anti-leukemic potential in refractory chronic myeloid leukemia. We look forward to collecting additional data from the pivotal Phase II trials and hope our work will soon benefit drug-resistant CML patients."

"The Phase I results on this third-generation BCR-ABL inhibitor have further demonstrated its clinical promise. HQP1351 returned to ASH (Free ASH Whitepaper) this year with an oral presentation and a nomination for ‘Best of ASH (Free ASH Whitepaper)’, all of which reaffirms the recognition of HQP1351’s potential clinical efficacy and safety by the international hematology community," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "There are three ongoing pivotal Phase II trials of HQP1351 in China, two of them have reached planned enrollment targets. The data readouts as well as an NDA submission in China are expected in 2020. In addition, the clinical development program of HQP1351 in the U.S. is ready to begin its patient enrollment. We hope HQP1351 will soon get the regulatory approval and reach the market to benefit drug-resistant CML patients in China and around the world."

About HQP1351

HQP1351 is a novel kinase inhibitor developed by Ascentage Pharma. It is an oral third-generation BCR-ABL inhibitor targeting a broad spectrum of BCR-ABL mutants, including those with the T315I mutation, to treat drug-resistant CML patients. A Phase I clinical trial for patients with TKI-resistant CML has been completed and the pivotal Phase II clinical trials are ongoing in China. In addition, a Phase Ib trial in patients with GIST and a Phase Ib trial are also ongoing in China and in the U.S., respectively.

CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST

On December 10, 2019 CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) reported that the on-going, global Phase III VOYAGER clinical trial of avapritinib, an investigational drug discovered by CStone’s partner, Blueprint Medicines, has completed target patient enrollment in China (Press release, CStone Pharmaceauticals, DEC 10, 2019, View Source [SID1234552211]). In addition, the VOYAGER trial’s enrollment target has been reached globally. The study was designed to evaluate the safety and efficacy of avapritinib as a third- or fourth-line treatment for patients with advanced gastrointestinal stromal tumors (GIST), in comparison with that of regorafenib, the current standard-of-care treatment for third-line GIST. On July 10, 2019, CStone announced the dosing of the first patient in China for the VOYAGER trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Blueprint Medicines expects to report top-line VOYAGER trial data in the second quarter of 2020. In August 2019, the U.S. Food & Drug Administration (FDA) accepted Blueprint Medicines’ New Drug Application (NDA) for avapritinib for the treatment of adult patients with PDGFRA Exon 18 mutant GIST, regardless of prior therapy, and fourth-line GIST. Subject to an initial approval of avapritinib, Blueprint Medicines plans to submit a supplemental NDA to the U.S. FDA for avapritinib for third-line GIST in the second half of 2020. CStone plans to submit an NDA for the treatment of third-line GIST to the China National Medical Products Administration (NMPA) in the second half of 2020.

GIST is the most common mesenchymal tumor of the GI tract, and it is most prevalent in patients aged 50 to 80. Around 90% of all GIST cases are associated with dysregulated cell growth due to mutations in KIT and PDGFRA tyrosine kinases. Existing data on regorafenib, the current standard third-line GIST treatment, shows a median progression-free survival of 4.8 months and an objective response rate (ORR) of only about 5%. There is currently no approved treatment for GIST patients who have failed third-line treatment. Thus, there are high unmet clinical needs in patients with third-line and later GIST.

Avapritinib is an investigational, orally available, potent and highly selective inhibitor of KIT and PDGFRA. Clinical data on avapritinib have demonstrated encouraging anti-tumor activity and benign tolerability in patients with PDGFRA Exon 18 mutants (primarily includes patients with the D842V mutation) and fourth-line GIST, two patient populations currently lacking effective therapies.

Data from the on-going Phase I NAVIGATOR trial were presented in November 2019 at the Connective Tissue Oncology Society Annual Meeting. As of the data cutoff date of November 16, 2018, these results showed:

An ORR of 86% (one response pending confirmation) in 43 response-evaluable patients with PDGFRA Exon 18 mutant GIST (including 38 patients with PDGFRα D842V-mutant GIST), and the median duration of response (DOR) was not reached.
An ORR of 22% (one response pending confirmation) and a median DOR of 10.2 months in 111 response-evaluable patients with fourth-line GIST.
Avapritinib was generally well-tolerated, and most adverse events were Grade 1 or 2 as assessed by investigators.
"We are pleased that in China, the global Phase III VOYAGER trial has completed its enrollment target sooner than planned, and this rapid progress reaffirms the urgent clinical needs of GIST patients in China," said Dr. Frank Jiang, Chairman and CEO of CStone. "With the appointment of Ms. Shirley Zhao, a seasoned pharmaceutical executive who has led the successful launches of numerous major brands, to the position of General Manager for Greater China and Head of Commercial, we are more confident than ever in our ability to accelerate CStone’s transition toward a commercial-stage company and to potentially bring avapritinib and other key assets to the China market."

CStone’s Chief Medical Officer, Dr. Jason Yang, noted: "GIST is a rare disease, and completing target enrollment in China in less than 4 months is a testament to the effective collaborations among CStone, investigators, and business partners. Currently available data on this highly selective inhibitor of KIT and PDGFRA mutant kinases has already demonstrated its clinical potential. At the same time, we are also conducting a Phase I/II bridging study of avapritinib in patients with advanced GIST in China."

About Avapritinib

Avapritinib is an investigational, oral precision therapy that selectively and potently inhibits KIT and PDGFRA mutant kinases. It is a type 1 inhibitor designed to target the active kinase conformation; all oncogenic kinases signal via this conformation. Avapritinib has demonstrated broad inhibition of KIT and PDGFRA mutations associated with GIST, including potent activity against activation loop mutations that are associated with resistance to currently approved therapies.

Blueprint Medicines is initially developing avapritinib for the treatment of advanced GIST, advanced systemic mastocytosis (SM), and indolent and smoldering SM. The U.S. FDA has granted Breakthrough Therapy Designation to avapritinib for two indications: one for the treatment of unresectable or metastatic GIST harboring the PDGFRA D842V mutation and one for the treatment of advanced SM, including the subtypes of aggressive SM, SM with an associated hematologic neoplasm and mast cell leukemia.

Blueprint Medicines has an exclusive collaboration and license agreement with CStone Pharmaceuticals for the development and commercialization of avapritinib and certain other drug candidates in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains development and commercial rights for avapritinib in the rest of the world.

Personalis, Inc. to Present at ESMO Immuno-Oncology Congress 2019

On December 10, 2019 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported that the company will participate in the ESMO (Free ESMO Whitepaper) Immuno-Oncology Congress 2019 in Geneva, Switzerland, December 11-14, including a poster presentation on December 12th (Press release, Personalis, DEC 10, 2019, View Source [SID1234552210]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster presentation, titled "A comprehensive tumor immunogenomics platform for precision immunotherapy: Enabling simultaneous characterization of tumors and the TME from a single FFPE sample," will describe the Personalis universal cancer immunogenomics platform, ImmunoID NeXT. The poster will provide an overview of how the platform can be used to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response; utilizing analytics including: human leukocyte antigen (HLA) typing and HLA loss of heterozygosity (LOH), neoantigen prediction and load, immune repertoire characterization, oncoviral detection, immune cell deconvolution, as well as the evaluation of tumor mutational burden (TMB) and microsatellite instability (MSI) status.

ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a single tumor specimen.

The presentation will be delivered by Robert Power, M.S., Product Manager, for Personalis.

Personalis will also be exhibiting during the conference (Exhibit #9). Representatives will be available to answer questions about the company’s cancer immunogenomics capabilities.